hydroxyurea and Leukemia, Myeloid, Acute studies

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research Excerpts

Excerpt	Relevance	Reference
"This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome."	9.19	Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014)
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."	9.19	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
"1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro."	9.13	Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. ( Camitta, B; Dubowy, R; Graham, M; Hakami, N; Kletzel, M; Mahoney, D; Newman, E; Ravindranath, Y, 2008)
"Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease."	8.83	Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006)
"Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown."	8.12	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022)
"Hyperleukocytosis occurs in 15-20% of all newly diagnosed acute myeloid leukemia patients and requires emergent treatment with leukapheresis or hydroxyurea when accompanied by signs or symptoms of leukostasis."	7.91	Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia. ( Auten, JJ; Clark, SM; Trepte, ML; van Deventer, HW, 2019)
"To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia."	7.75	A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009)
"The leukemogenic risk attributed to therapy of polycythemia vera with radiophosphorus and alkylating drugs has led, over the last 20 years, to the increased use of myelosupressive nonmutagenic drugs, especially hydroxyurea."	7.71	Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. ( Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Nebesnáková, E; Raffac, S; Stecová, N; Svorcová, E; Tóthová, E, 2001)
"The authors present two patients with polycythemia vera where they recorded after several years' treatment with hydroxyurea development of acute myeloblastic leukaemia."	7.70	[Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities]. ( Fricová, M; Kafková, A; Nebesnáková, E; Stecová, N; Tóthová, E, 1999)
"Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)."	6.73	Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008)
"Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis."	5.62	Management of hydroxyurea resistant or intolerant polycythemia vera. ( Pasricha, SR; Prince, HM; Raman, I; Yannakou, CK, 2021)
"A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 micrograms/kg i."	5.28	Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. ( Archimbaud, E; Devaux, Y; Fiere, D; French, M; Guyotat, D; Moriceau, M; Sebban, C; Troncy, J; Viala, JJ, 1989)
"This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome."	5.19	Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014)
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."	5.19	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
"1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro."	5.13	Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. ( Camitta, B; Dubowy, R; Graham, M; Hakami, N; Kletzel, M; Mahoney, D; Newman, E; Ravindranath, Y, 2008)
" As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0."	5.11	Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005)
" An algorithm for the treatment of patients with erythremia is proposed along with recommendations on the use of aspirin, hydroxyurea, alpha-interpheron, and imatinib."	4.88	[True polycythemia: current views of pathogenesis, diagnostics and treatment]. ( Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT, 2012)
"Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease."	4.83	Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006)
" Treatment selection is based on a patient's age and a history of thrombosis in patients with low-risk PV treated with therapeutic phlebotomy and aspirin alone, whereas cytoreductive therapy with either hydroxyurea or interferon alfa (IFN-α) is added for high-risk disease."	4.31	Moving toward disease modification in polycythemia vera. ( Bewersdorf, JP; Bose, P; How, J; Masarova, L; Mascarenhas, J; Pemmaraju, N; Rampal, RK, 2023)
"Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown."	4.12	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022)
"Hyperleukocytosis occurs in 15-20% of all newly diagnosed acute myeloid leukemia patients and requires emergent treatment with leukapheresis or hydroxyurea when accompanied by signs or symptoms of leukostasis."	3.91	Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia. ( Auten, JJ; Clark, SM; Trepte, ML; van Deventer, HW, 2019)
"To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia."	3.75	A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009)
" In this study, we utilized these synergistic effects of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]), hydroxyurea, and low-dose cytosine arabinoside to treat elderly patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)."	3.73	GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. ( Chan, GW; Miller, KB; Winer, ES, 2005)
"The leukemogenic risk attributed to therapy of polycythemia vera with radiophosphorus and alkylating drugs has led, over the last 20 years, to the increased use of myelosupressive nonmutagenic drugs, especially hydroxyurea."	3.71	Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. ( Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Nebesnáková, E; Raffac, S; Stecová, N; Svorcová, E; Tóthová, E, 2001)
"The authors present two patients with polycythemia vera where they recorded after several years' treatment with hydroxyurea development of acute myeloblastic leukaemia."	3.70	[Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities]. ( Fricová, M; Kafková, A; Nebesnáková, E; Stecová, N; Tóthová, E, 1999)
"Metronomic chemotherapy could prolong survival time of unfit AML patients, especially in the first 12 months after diagnosis without increasing treatment-associated adverse events."	2.94	Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial. ( Charoenprasert, K; Chinthammitr, Y; Kasyanan, H; Panoi, N; Phinyo, P; Pongudom, S; Purattanamal, J; Surawong, A; Wongyai, K, 2020)
"We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine."	2.87	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. ( Almakadi, M; Aslostovar, L; Bhatia, M; Boyd, AL; Collins, TJ; Foley, R; Julian, JA; Kim, RB; Leber, B; Leong, DP; Levine, MN; Tirona, RG; Xenocostas, A, 2018)
"SIRs for acute myelogenous leukemia (AML) were high in ET patients."	2.87	Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. ( Achenbach, H; Besses, C; Birgegård, G; Folkvaljon, F; Garmo, H; Griesshammer, M; Gugliotta, L; Harrison, CN; Holmberg, L; Kiladjian, JJ; Wu, J, 2018)
"Leukostasis is a life-threatening complication of high concentrations of circulating leukemic cells, most often myeloblasts."	2.82	Hyperleukocytosis and leukostasis in acute and chronic leukemias. ( Macaron, W; Sargsyan, Z; Short, NJ, 2022)
"Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)."	2.73	Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008)
"Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage."	2.49	[Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013)
"Leukemic cells from many patients with acute myelogenous leukemia (AML) have surface receptors for CSFs and may proliferate in response to CSFs."	2.40	Cytokine therapy for hematological malignancies. ( Ezaki, K; Tsuzuki, M, 1997)
"Hydroxyurea (HU) is a guideline-recommended cytoreductive therapy for patients at high risk for MPNs."	1.91	Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. ( Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Shallis, RM; Stempel, JM; Wang, R; Zeidan, AM, 2023)
"Patients with hyperleukocytic (HL) acute myeloid leukemia (AML) are at higher risk of early death."	1.72	Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. ( Adès, L; Azoulay, E; Boissel, N; Chevret, S; Fodil, S; Itzykson, R; Lengliné, E; Mariotte, E; Rabian, F; Raffoux, E; Rouzaud, C; Sébert, M; Valade, S; Zafrani, L, 2022)
"Newly diagnosed acute myeloid leukemia is often deemed a medical emergency, requiring urgent treatment."	1.72	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. ( Borthakur, G; Brandt, M; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Kim, K; Konopleva, M; Loghavi, S; Pemmaraju, N; Pierce, S; Rausch, CR; Ravandi, F; Sasaki, K; Short, NJ; Tang, G; Yilmaz, M, 2022)
"Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis."	1.62	Management of hydroxyurea resistant or intolerant polycythemia vera. ( Pasricha, SR; Prince, HM; Raman, I; Yannakou, CK, 2021)
"Its potential long-term risk for carcinogenesis or leukemogenic risk remains undefined."	1.51	Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. ( El-Deiry, WS; Finnberg, NK; Pu, JJ; Regan, S; Yang, X, 2019)
"In conclusion, patients with acute myeloid leukemia receiving chemotherapy should be monitored for active CMV infection."	1.36	Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia. ( Capobianchi, A; Capria, S; Cardarelli, L; Foà, R; Gentile, G; Gianfelici, V; Martino, P; Meloni, G; Trisolini, SM, 2010)
"Acute myeloid leukemia was finally diagnosed in October 1998, and chromosomal analysis disclosed inv(3) in addition to -5 and -7."	1.31	[Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer]. ( Aoki, K; Chiba, S; Hirai, H; Honda, H; Horikoshi, M; Itikawa, M; Kurokawa, M; Machida, U; Masuda, S; Mitani, K; Ogawa, S; Seo, S; Sunaga, S; Yazaki, Y, 2000)
"Hydroxyurea is an established drug that has been used for the treatment of myeloproliferative disorders and some solid tumors for some time."	1.31	Are we underestimating the leukemogenic risk of hydroxyurea. ( Al-Dabbous, IA; Al-Jam'a, AH; Al-Khatti, AA; Esan, FG, 2002)
"A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 micrograms/kg i."	1.28	Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. ( Archimbaud, E; Devaux, Y; Fiere, D; French, M; Guyotat, D; Moriceau, M; Sebban, C; Troncy, J; Viala, JJ, 1989)
" The dose-response relationship between TPA concentration and induced differentiation is relatively steep."	1.27	Induction of HL-60 monocytic cell differentiation promoted by a perturbation of DNA synthesis: hydroxyurea promotes action of TPA. ( Fishbaugh, J; Freeman, L; Yen, A, 1988)
"Leucocytes from patients with chronic myelogenous leukemia had higher repair synthesis after Neocarzinostatin treatment compared to those from patients with acute leukemia."	1.26	DNA repair in human leukemic leucocytes treated with neocarzinostatin. ( Nakamura, T; Sasada, M; Sawada, H; Uchino, H, 1978)
"Hydroxyurea was administered orally to prevent the effects of leukostasis in adults with acute leukemia who had peripheral blast cell counts greater than 100,000/cu mm."	1.26	Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. ( Armitage, JO; Burns, P; Grund, FM, 1977)

Research

Studies (130)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Number of Participants With Thrombotic and Haemorrhagic Events

Timeframe	Studies, this research(%)	All Research%
pre-1990	46 (35.38)	18.7374
1990's	10 (7.69)	18.2507
2000's	23 (17.69)	29.6817
2010's	35 (26.92)	24.3611
2020's	16 (12.31)	2.80

Authors	Studies
Macaron, W	1
Sargsyan, Z	1
Short, NJ	2
Kim, K	1
Konopleva, M	2
DiNardo, CD	1
Borthakur, G	1
Loghavi, S	1
Tang, G	1
Daver, N	1
Pemmaraju, N	2
Jabbour, E	1
Rausch, CR	1
Yilmaz, M	1
Sasaki, K	1
Jain, N	1
Brandt, M	1
Pierce, S	1
Garcia-Manero, G	1
Ravandi, F	1
Kantarjian, H	1
Kadia, TM	1
Alvarez-Larrán, A	3
Garrote, M	1
Ferrer-Marín, F	2
Pérez-Encinas, M	1
Mata-Vazquez, MI	1
Bellosillo, B	2
Arellano-Rodrigo, E	1
Gómez, M	2
García, R	1
García-Gutiérrez, V	1
Gasior, M	1
Cuevas, B	1
Angona, A	2
Gómez-Casares, MT	2
Martínez, CM	1
Magro, E	1
Ayala, R	1
Del Orbe-Barreto, R	1
Pérez-López, R	1
Fox, ML	1
Raya, JM	1
Guerrero, L	1
García-Hernández, C	1
Caballero, G	1
Murillo, I	1
Xicoy, B	2
Ramírez, MJ	1
Carreño-Tarragona, G	1
Hernández-Boluda, JC	2
Pereira, A	1
Fodil, S	1
Chevret, S	2
Rouzaud, C	1
Valade, S	1
Rabian, F	2
Mariotte, E	1
Raffoux, E	3
Itzykson, R	2
Boissel, N	3
Sébert, M	2
Adès, L	2
Zafrani, L	1
Azoulay, E	3
Lengliné, E	3
Wang, R	1
Shallis, RM	2
Stempel, JM	1
Huntington, SF	1
Zeidan, AM	3
Gore, SD	1
Ma, X	1
Podoltsev, NA	1
Singh, C	1
Wadhera, S	1
Yanamandra, U	1
Karunakaran, P	1
Jindal, N	1
Kumar, SR	1
Saini, N	1
Jandial, A	1
Jain, A	1
Das, C	1
Prakash, G	1
Khadwal, A	1
Naseem, S	1
Das, R	1
Varma, N	1
Varma, S	1
Malhotra, P	1
Lad, D	1
Bewersdorf, JP	2
How, J	1
Masarova, L	1
Bose, P	1
Mascarenhas, J	1
Rampal, RK	1
Regan, S	1
Yang, X	1
Finnberg, NK	1
El-Deiry, WS	1
Pu, JJ	1
Grønningsæter, IS	1
Fredly, HK	1
Gjertsen, BT	2
Hatfield, KJ	1
Bruserud, Ø	2
Cerrano, M	1
Seegers, V	1
Lemiale, V	2
Dombret, H	3
Pongudom, S	1
Phinyo, P	1
Chinthammitr, Y	1
Charoenprasert, K	1
Kasyanan, H	1
Wongyai, K	1
Purattanamal, J	1
Panoi, N	1
Surawong, A	1
Österroos, A	1
Eriksson, A	1
Antunovic, P	1
Cammenga, J	1
Deneberg, S	1
Lazarevic, V	1
Lorenz, F	1
Möllgård, L	2
Derolf, ÅR	2
Uggla, B	1
Wennström, L	1
Ölander, E	1
Höglund, M	1
Juliusson, G	1
Lehmann, S	1
Giri, S	1
Tallman, MS	1
Stahl, M	1
Diao, S	1
Nichols, ED	1
DiNardo, C	1
Ning, J	1
Qiao, W	1
Maiti, A	1
DiPippo, AJ	1
Raman, I	1
Pasricha, SR	1
Prince, HM	1
Yannakou, CK	1
Patel, PA	1
Lapp, SA	1
Grubbs, G	1
Edara, VV	1
Rostad, CA	1
Stokes, CL	1
Pauly, MG	1
Anderson, EJ	1
Piantadosi, A	1
Suthar, MS	1
Khurana, S	1
Sabnis, HS	1
Xu, X	1
Xu, Y	1
Guo, R	2
Xu, R	1
Fu, C	1
Xing, M	1
Sasanuma, H	1
Li, Q	1
Takata, M	1
Takeda, S	1
Xu, D	1
Huang, X	1
Ma, T	1
Zhu, Y	1
Jiao, B	1
Yu, S	1
Wang, K	1
Mi, JQ	1
Ren, R	1
Park, S	1
Hamel, JF	1
Toma, A	1
Kelaidi, C	1
Thépot, S	1
Campelo, MD	1
Santini, V	1
Sekeres, MA	1
Balleari, E	1
Kaivers, J	1
Sapena, R	1
Götze, K	1
Müller-Thomas, C	1
Beyne-Rauzy, O	1
Stamatoullas, A	1
Kotsianidis, I	1
Komrokji, R	1
Steensma, DP	1
Fensterl, J	1
Roboz, GJ	1
Bernal, T	1
Ramos, F	1
Calabuig, M	1
Guerci-Bresler, A	1
Bordessoule, D	2
Cony-Makhoul, P	1
Cheze, S	1
Wattel, E	1
Rose, C	1
Vey, N	1
Gioia, D	1
Ferrero, D	2
Gaidano, G	2
Cametti, G	1
Pane, F	1
Sanna, A	1
Germing, U	1
Sanz, GF	1
Dreyfus, F	1
Fenaux, P	1
Kubesova, B	1
Pavlova, S	1
Malcikova, J	1
Kabathova, J	1
Radova, L	1
Tom, N	1
Tichy, B	1
Plevova, K	1
Kantorova, B	1
Fiedorova, K	1
Slavikova, M	1
Bystry, V	1
Kissova, J	1
Gisslinger, B	1
Gisslinger, H	1
Penka, M	1
Mayer, J	1
Kralovics, R	1
Pospisilova, S	1
Doubek, M	1
Trepte, ML	1
Auten, JJ	1
Clark, SM	1
van Deventer, HW	1
Xu, ML	1
Curtis, SA	1
Medoff, E	1
Mixon, R	1
Folkers, A	1
Aslostovar, L	1
Boyd, AL	1
Almakadi, M	1
Collins, TJ	1
Leong, DP	1
Tirona, RG	1
Kim, RB	1
Julian, JA	1
Xenocostas, A	1
Leber, B	1
Levine, MN	1
Foley, R	1
Bhatia, M	1
Wang, HY	1
Dell'Aquila, ML	1
Dvanajscak, Z	1
Bejar, R	1
Broome, HE	1
Hsi, E	1
Murray, SS	1
Thorson, JA	1
Birgegård, G	1
Folkvaljon, F	1
Garmo, H	1
Holmberg, L	1
Besses, C	3
Griesshammer, M	1
Gugliotta, L	1
Wu, J	1
Achenbach, H	1
Kiladjian, JJ	1
Harrison, CN	2
Abruzzese, E	1
Trawinska, MM	1
Neri, B	1
Bondanini, F	1
Fratoni, S	1
Tendas, A	1
Scaramucci, L	1
Siniscalchi, A	1
Giovannini, M	1
Palumbo, R	1
de Fabritiis, P	2
Niscola, P	1
Bertoli, S	1
Tavitian, S	1
Picard, M	1
Huguet, F	1
Vergez, F	1
Delabesse, E	1
Sarry, A	1
Bérard, E	1
Récher, C	1
Levin, M	1
Stark, M	1
Berman, B	1
Assaraf, YG	1
Tomlinson, BK	1
Tuscano, JM	1
Abedi, M	1
Welborn, J	1
Arora, M	1
O'Donnell, RT	1
Wun, T	1
Jonas, BA	1
Cervantes, F	2
Fu, R	1
Zhang, L	1
Yang, R	1
Nand, S	3
Othus, M	2
Godwin, JE	2
Willman, CL	1
Norwood, TH	1
Howard, DS	1
Coutre, SE	1
Erba, HP	2
Appelbaum, FR	2
Willemze, R	2
Suciu, S	2
Muus, P	2
Halkes, CJ	1
Meloni, G	3
Meert, L	2
Karrasch, M	1
Rapion, J	1
Vignetti, M	2
Amadori, S	2
de Witte, T	2
Marie, JP	2
Thol, F	1
Schlenk, RF	1
Martínez-Avilés, L	1
Antelo, ML	1
Burgaleta, C	1
Mata, MI	1
Martínez-Trillos, A	1
Durán, MA	1
Marcote, B	1
Ancochea, A	1
Senín, A	1
Vicente, V	1
Castro, O	1
Nouraie, M	1
Oneal, P	1
Björkholm, M	1
Hultcrantz, M	1
Stein, BL	1
Moliterno, AR	1
Tiu, RV	1
Kuo, KH	1
Callum, JL	1
Panzarella, T	1
Jacks, LM	1
Brandwein, J	1
Crump, M	1
Curtis, JE	1
Gupta, V	1
Lipton, JH	1
Minden, MD	1
Sher, GD	1
Schimmer, AD	1
Schuh, AC	1
Yee, KW	1
Keating, A	1
Messner, HA	1
Ly, T	1
Endo, A	1
Lamond, AI	1
Aylı, M	1
Özcan, M	1
Cengiz Seval, G	1
Selleslag, D	1
Aversa, F	1
Musso, M	1
Annino, L	1
Venditti, A	1
Voso, MT	1
Mazzone, C	1
Magro, D	1
Alimena, G	3
Mancini, M	2
Hagemeijer, A	1
Paoloni, F	1
Fazi, P	1
Ramadan, SM	1
Baron, F	1
Leitch, C	1
Osdal, T	1
Andresen, V	1
Molland, M	1
Kristiansen, S	1
Nguyen, XN	1
McCormack, E	1
Achille, NJ	1
Phelan, K	1
Zhang, S	1
Cooper, K	1
Radich, JP	1
Zeleznik-Le, NJ	1
Mamez, AC	1
Canet, E	1
Schlemmer, B	1
Nazha, A	1
Gerds, AT	1
Badawy, SM	1
Huang, CT	1
Kuo, PH	1
Yao, M	1
Tsai, YJ	1
Yang, PC	1
Godwin, J	1
Smith, S	1
Barton, K	1
Michaelis, L	1
Alkan, S	1
Veerappan, R	1
Rychlik, K	1
Germano, E	1
Stiff, P	1
Grant, R	1
Keidan, J	1
Harousseau, JL	1
Martinelli, G	1
Jedrzejczak, WW	1
Brandwein, JM	1
Masszi, T	1
Ossenkoppele, GJ	1
Alexeeva, JA	1
Beutel, G	1
Maertens, J	1
Vidriales, MB	1
Thomas, X	1
Burnett, AK	1
Robak, T	2
Khuageva, NK	1
Golenkov, AK	1
Tothova, E	3
Park, YC	1
Bessems, A	1
De Porre, P	1
Howes, AJ	1
Li, QB	1
Li, L	1
You, Y	1
Chen, ZC	1
Xia, LH	1
Zou, P	1
Boehm, A	1
Mayerhofer, M	1
Herndlhofer, S	1
Knoebl, P	1
Sillaber, C	1
Sperr, WR	1
Jaeger, U	1
Valent, P	1
Dingli, D	1
Tefferi, A	1
Capria, S	1
Gentile, G	1
Capobianchi, A	1
Cardarelli, L	1
Gianfelici, V	1
Trisolini, SM	1
Foà, R	1
Martino, P	1
Alam, F	1
Chin, KJ	1
Taylor, JG	1
Darbari, DS	1
Darari, DS	1
Maric, I	1
McIver, Z	1
Arthur, DC	1
Vatutin, NT	1
Taradin, GG	1
Bakhteeva, TD	1
Kalinkina, NV	1
Skliannaia, EV	1
Al-Jam'a, AH	1
Al-Dabbous, IA	1
Al-Khatti, AA	1
Esan, FG	1
Petti, MC	3
Tafuri, A	1
Latagliata, R	3
Aloe Spiriti, MA	1
Montefusco, E	2
Petrucci, MT	1
Spadea, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547]		8,670 participants (Anticipated)	Observational	2019-09-30	Recruiting
A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease[NCT02096289]	Phase 1	13 participants (Actual)	Interventional	2014-07-31	Completed
A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.[NCT00202644]	Phase 4	150 participants (Actual)	Interventional	2006-01-13	Completed
A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia[NCT00658814]	Phase 2	133 participants (Actual)	Interventional	2008-12-01	Active, not recruiting
Vinblastine Versus Oral Hydroxiurea in Newly Diagnosed AML With Hyperleukocytosis: a Phase 2 Clinical Study[NCT05062278]	Phase 2	46 participants (Anticipated)	Interventional	2021-07-26	Recruiting
Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP[NCT00091234]	Phase 2/Phase 3	279 participants (Anticipated)	Interventional	2004-06-30	Recruiting
A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or Older (Farnesyl Transferase Inhibition Global Human Trials AML 301 [F.I.G.H.T. AM[NCT00093990]	Phase 3	457 participants (Actual)	Interventional	2004-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Thrombohaemorrhagic events are a well-known complication of the underlying essential thrombocythemia (ET) and disease progression. Events such as arterial and venous thrombosis, serious haemorrhage (including gastrointestinal haemorrhage), and death from vascular causes have been reported in participants who received cytoreductive treatment. (NCT00202644)
Timeframe: From the signing of informed consent until the last study-related visit (Month 36)

Percentage of Participants With Complete Response

Intervention	participants (Number)
Anagrelide	30
Hydroxyurea	16

A complete response was defined as a platelet count of less than (<) 400x10^9/Liter which was confirmed over 2 consecutive visits at least 28 days apart. (NCT00202644)
Timeframe: Baseline up to Month 36

Percentage of Participants With Partial Response

Intervention	percenatge of participants (Number)
Anagrelide	58.9
Hydroxyurea	58.8

A partial response is defined as a platelet count of 400-600 x 10^9/Liter and a reduction in platelet count of at least 200 x 10^9/Liter from baseline which was confirmed over 2 consecutive visits at least 28 days apart. (NCT00202644)
Timeframe: Baseline up to Month 36

Platelet Count at Month 6

Time to Complete Response

Intervention	percentage of participants (Number)
Anagrelide	21.9
Hydroxyurea	27.9

Intervention	10^9 platelets per liter (Mean)
Anagrelide	418.6
Hydroxyurea	396.0

Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a participant did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). (NCT00202644)
Timeframe: Baseline up to Month 36

Time to Partial Response

Intervention	days (Median)
Anagrelide	177.0
Hydroxyurea	123.0

Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time

Intervention	days (Median)
Anagrelide	61.0
Hydroxyurea	47.0

The LVEF was measured by echocardiography and considered a sufficiently sensitive measure to evaluate any changes in cardiac function. (NCT00202644)
Timeframe: Baseline and Month 1, 2, 3, 6, 9, 12, 18, 24, 30 and 36

Change From Baseline in Platelet Counts at Month 3 and 36

Intervention	percentage of ejection fraction (Mean)
	Baseline	Change from baseline at Month 1	Change from baseline at Month 2	Change from baseline at Month 3	Change from baseline at Month 6	Change from baseline at Month 9	Change from baseline at Month 12	Change from baseline at Month 18	Change from baseline at Month 24	Change from baseline at Month 30	Change from baseline at Month 36
Anagrelide	66.4	0.5	1.2	0.1	-0.5	-0.8	-0.8	-2.0	-1.8	-1.8	-1.7
Hydroxyurea	66.9	-1.1	0	-0.4	-0.6	-1.5	-0.6	-1.2	-1.7	-0.2	-0.6

Platelet count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 3 and 36

Change From Baseline in Red Blood Cell Count Over Time

Intervention	10^9 platelets per liter (Mean)
	Change from baseline at Month 3	Change from baseline at Month 36
Anagrelide	575.3	531.0
Hydroxyurea	462.2	462.8

Red blood cell count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 6, 12, 18, 24, 30 and 36

Change From Baseline in White Blood Cell Count Over Time

Intervention	10^12 cells per liter (Mean)
	Baseline	Change from baseline at Month 6	Change from baseline at Month 12	Change from baseline at Month 18	Change from baseline at Month 24	Change from baseline at Month 30	Change from baseline at Month 36
Anagrelide	4.757	-0.227	-0.246	-0.225	-0.299	-0.295	-0.366
Hydroxyurea	4.787	-1.467	-1.398	-1.323	-1.281	-1.339	-1.362

White blood cell count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 6, 12, 18, 24, 30 and 36

30-Day Survival

Intervention	10^9 cells per liter (Mean)
	Baseline	Change from baseline at Month 6	Change from baseline at Month 12	Change from baseline at Month 18	Change from baseline at Month 24	Change from baseline at Month 30	Change from baseline at Month 36
Anagrelide	9.13	-0.38	-1.00	-1.18	-1.24	-1.00	-1.63
Hydroxyurea	10.20	-5.02	-4.79	-4.46	-4.82	-4.59	-4.46

Patients surviving more than 30 days after study registration (NCT00658814)
Timeframe: 30 days

Complete Response

Intervention	percentage of participants (Number)
Good Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin	92
Poor Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin	87

Morphologic complete remission (CR): ANC >=1,000/mcL, platelet count >=100,000/mcL, <5% bone marrow blasts, no Auer rods, no evidence of extramedullary disease. Morphologic complete remission with incomplete blood count recovery (CRi): Same as CR but ANC may be <1,000/mcL and/or platelet count <100,000/mcL. (NCT00658814)
Timeframe: Up to 60 days

Relapse-free Survival

Intervention	percentage of participants (Number)
Good Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin	44
Poor Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin	35

Relapse-free survival (RFS) is defined for all patients who achieve CR or CRi. RFS is measured from the date CR or CRi is first achieved until relapse or death form any cause, with observation censored on the date of last contact for patients last known to be alive without report of relapse. Relapse from CR/CRi is defined as reappearance of leukemic blasts in the peripheral blood; or > 5% blasts in the bone marrow not attributable to another cause; or appearance or reappearance of extramedullary disease. (NCT00658814)
Timeframe: Up to 5 years

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug

Intervention	months (Median)
Good Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin	8
Poor Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin	7

Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00658814)
Timeframe: Up to 5 years

Intervention	Participants (Number)
	ALT, SGPT (serum glutamic pyruvic transaminase)	AST, SGOT	Adult respiratory distress syndrome (ARDS)	Albumin, serum-low (hypoalbuminemia)	Anorexia	Bilirubin (hyperbilirubinemia)	Calcium, serum-low (hypocalcemia)	Carbon monoxide diffusion capacity (DL(co))	Cardiac Arrhythmia-Atrial fibrilation	Cardiac General-cardiopulmonary disease	Cardiac General-Chest Pain	Cardiac troponin I (cTnI)	Cardiac-ischemia/infarction	Conduction abnormality NOS	Confusion	Constipation	Cytokine release syndrome/acute infusion reaction	Death - Disease progression NOS	Death - Multi-organ failure	Death not associated with CTCAE term - Death NOS	Dehydration	Diarrhea	Dyspnea (shortness of breath)	Edema: limb	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Glucose, serum-high (hyperglycemia)	Hemoglobin	Hemorrhage, CNS	Hemorrhage, GI - Stomach	Hemorrhage, GI - Upper GI NOS	Hemorrhage/Bleeding-platelets and red blood cells	Hepatobiliary/Pancreas-venoocclusive disease	Hypertension	Hypotension	Hypoxia	Inf (clin/microbio) w/Gr 3-4 neuts - Blood	Inf (clin/microbio) w/Gr 3-4 neuts - Catheter-rel	Inf (clin/microbio) w/Gr 3-4 neuts - Colon	Inf (clin/microbio) w/Gr 3-4 neuts - Conjunctiva	Inf (clin/microbio) w/Gr 3-4 neuts - Dental-tooth	Inf (clin/microbio) w/Gr 3-4 neuts - Kidney	Inf (clin/microbio) w/Gr 3-4 neuts - Lung	Inf (clin/microbio) w/Gr 3-4 neuts - Oral cav-gums	Inf (clin/microbio) w/Gr 3-4 neuts - Sinus	Inf (clin/microbio) w/Gr 3-4 neuts - Skin	Inf (clin/microbio) w/Gr 3-4 neuts - UTI	Inf w/normal ANC or Gr 1-2 neutrophils - Blood	Inf w/normal ANC or Gr 1-2 neutrophils - Lung	Inf w/normal ANC or Gr 1-2 neutrophils - Skin	Infection with unknown ANC - Blood	Infection with unknown ANC - Lung (pneumonia)	Infection with unknown ANC - Skin (cellulitis)	Infection-Aspirgillosis	Infection-bacteremia	Left ventricular systolic dysfunction	Leukocytes (total WBC)	Liver dysfunction/failure (clinical)	Lymphopenia	Mood alteration - depression	Mucositis/stomatitis (functional/symp) - Oral cav	Muscle weakness, not d/t neuropathy - body/general	Neutrophils/granulocytes (ANC/AGC)	Pain - Cardiac/heart	Petechiae/purpura (hemorrhage into skin or mucosa)	Phosphate, serum-low (hypophosphatemia)	Platelets	Pleural effusion (non-malignant)	Pneumonitis/pulmonary infiltrates	Potassium, serum-low (hypokalemia)	Pulmonary/Upper Respiratory-pulmonary edema	Rash/desquamation	SVT and nodal arrhythmia - Atrial fibrillation	SVT and nodal arrhythmia - SVT tachycardia	Sodium, serum-low (hyponatremia)	Sudden death	Thrombosis/thrombus/embolism
Consolidation Therapy	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	18	1	0	0	0	0	21	0	0	0	12	0	0	0	0	0	0	0	0	0	0
Maintenance Therapy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	2	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	6	0	1	0	0	0	10	0	0	0	3	0	0	0	0	0	0	0	0	0	0
Remission Induction Chemotherapy	5	4	1	5	5	3	6	1	1	1	1	1	1	1	1	2	1	1	2	1	1	2	5	1	18	50	10	73	1	1	1	1	1	1	2	4	16	2	1	1	3	1	8	1	2	6	3	2	0	1	1	1	1	1	1	1	80	0	23	2	1	4	85	2	1	4	85	1	1	5	2	1	2	1	5	1	2

Article	Year
Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leukemia & lymphoma, 2022, Volume: 63, Issue:8 Topics: Chronic Disease; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Leukost	2022
Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis. Transfusion, 2020, Volume: 60, Issue:10 Topics: Disease-Free Survival; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; R	2020
Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies. Annals of hematology, 2018, Volume: 97, Issue:11 Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; Azacitidine; Blood	2018
[Treatment of essential thrombocythemia]. Medicina clinica, 2013, Sep-21, Volume: 141, Issue:6 Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress	2013
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression;	2013
Gemtuzumab ozogamicin in acute myeloid leukemia revisited. Expert opinion on biological therapy, 2014, Volume: 14, Issue:8 Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap	2014
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:2 Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Ja	2014
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Annals of hematology, 2014, Volume: 93, Issue:12 Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression	2014
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? The oncologist, 2016, Volume: 21, Issue:4 Topics: Busulfan; Cell Proliferation; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Acute; Nitrile	2016
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. Current hematologic malignancy reports, 2006, Volume: 1, Issue:2 Topics: Aged; Agranulocytosis; Alkylating Agents; Clinical Trials as Topic; Combined Modality Therapy; Disea	2006
[True polycythemia: current views of pathogenesis, diagnostics and treatment]. Klinicheskaia meditsina, 2012, Volume: 90, Issue:8 Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hema	2012
Fatal hemorrhagic pneumonia caused by infection due to Kytococcus sedentarius--a pathogen or passenger? Annals of hematology, 2004, Volume: 83, Issue:7 Topics: Actinomycetales; Actinomycetales Infections; Acyclovir; Antineoplastic Combined Chemotherapy Protoco	2004
Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Annals of hematology, 1996, Volume: 72, Issue:2 Topics: Acute Disease; Aged; Allopurinol; Anemia, Refractory; Anti-Bacterial Agents; Biopsy; Blood Cell Coun	1996
Cytokine therapy for hematological malignancies. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 1 Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Granulocyte	1997
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. Bone marrow transplantation, 2001, Volume: 28, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation	2001
Current concepts in the treatment of chronic myelocytic leukemia. Annual review of medicine, 1973, Volume: 24 Topics: Antineoplastic Agents; Blood Platelet Disorders; Bromine; Busulfan; Dose-Response Relationship, Drug	1973
[New principles of treatment in acute leukemia]. Ugeskrift for laeger, 1970, Apr-30, Volume: 132, Issue:18 Topics: Adolescent; Adult; Antineoplastic Agents; Central Nervous System Diseases; Child; Cyclophosphamide;	1970

Article	Year
Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial. Asian Pacific journal of cancer prevention : APJCP, 2020, Jan-01, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; Humans;	2020
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood advances, 2018, 08-14, Volume: 2, Issue:15 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dopamine D2 Receptor Antagonists;	2018
Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leukemia research, 2018, Volume: 74 Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukem	2018
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. American journal of hematology, 2019, Volume: 94, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Doxorubi	2019
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood, 2013, Nov-14, Volume: 122, Issue:20 Topics: Age Factors; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineopla	2013
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p Annals of hematology, 2014, Volume: 93, Issue:6 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides	2014
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Annals of hematology, 2014, Volume: 93, Issue:12 Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres	2014
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-20, Volume: 34, Issue:9 Topics: Age Factors; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineopla	2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leukemia research, 2016, Volume: 42 Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto	2016
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leukemia & lymphoma, 2008, Volume: 49, Issue:11 Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;	2008
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood, 2009, Aug-06, Volume: 114, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female;	2009
Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. European journal of internal medicine, 2009, Volume: 20, Issue:8 Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined	2009
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F	2005
Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:5 Topics: Adolescent; Adult; Child; Child, Preschool; Cytarabine; Humans; Hydroxyurea; Infections; Leukemia; L	2008
Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase. Cancer research, 1984, Volume: 44, Issue:1 Topics: Adult; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Follow-Up Studies; Humans; Hyd	1984
Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. American journal of hematology, 1995, Volume: 49, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cell C	1995
[Treatment of polycythemia with 32P with or without hydroxyurea maintenance therapy. Preliminary results in 237 elderly and high vascular risk subjects studied since 1980]. Presse medicale (Paris, France : 1983), 1993, Dec-11, Volume: 22, Issue:39 Topics: Age Factors; Aged; Carcinoma; Cardiovascular Diseases; Female; Humans; Hydroxyurea; Injections, Intr	1993
A case-control study of the effects of hydroxyurea on circulating cortisol levels in patients with acute myelogenous leukemia and chronic myeloproliferative disorders. Pharmacological research, 2000, Volume: 42, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Case-Control Studies; Chronic Disease; Drug Interactions; Female	2000
[Combination chemotherapy in acute blast crisis of chronic myeloid leukaemia (author's transl)]. Deutsche medizinische Wochenschrift (1946), 1977, Aug-12, Volume: 102, Issue:32 Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid;	1977
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Medical and pediatric oncology, 1979, Volume: 6, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cyclophospha	1979
[Treatment of acute myeloblastic leukemia in aged patients]. Presse medicale (Paris, France : 1983), 1989, Mar-11, Volume: 18, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C	1989
[AML-7 study of the value of intensive remission induction in aged patients with acute myelocytic leukemia]. Onkologie, 1985, Volume: 8, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorub	1985
[AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients]. Onkologie, 1985, Volume: 8, Issue:3 Topics: Adult; Age Factors; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined	1985

Article	Year
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American journal of hematology, 2022, Volume: 97, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical	2022
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer, 2022, 07-01, Volume: 128, Issue:13 Topics: Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Nitriles; Poly	2022
Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. PloS one, 2022, Volume: 17, Issue:7 Topics: Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Proportional Hazards Models; Recurrence; Remission In	2022
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood advances, 2023, 03-14, Volume: 7, Issue:5 Topics: Aged; Aged, 80 and over; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Medicare; Myelodysplastic Sy	2023
High-dose hydroxyurea with differentiating agents for treating ultra-high-risk acute promyelocytic leukemia in resource-challenged settings. Acta oncologica (Stockholm, Sweden), 2022, Volume: 61, Issue:12 Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute	2022
Moving toward disease modification in polycythemia vera. Blood, 2023, Nov-30, Volume: 142, Issue:22 Topics: Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid, Acute; Polycythemia Vera;	2023
Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. Cancer biology & therapy, 2019, Volume: 20, Issue:11 Topics: Adult; Anemia, Sickle Cell; Carcinogenesis; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromo	2019
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells, 2019, 10-10, Volume: 8, Issue:10 Topics: Aged; Aged, 80 and over; Amino Acids; Cytarabine; Drug Therapy; Female; Humans; Hydroxyurea; Leukemi	2019
Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis. Leukemia & lymphoma, 2020, Volume: 61, Issue:3 Topics: Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukocytosis	2020
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years. British journal of haematology, 2020, Volume: 189, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; De	2020
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax. American journal of hematology, 2021, 03-01, Volume: 96, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds,	2021
Management of hydroxyurea resistant or intolerant polycythemia vera. Leukemia & lymphoma, 2021, Volume: 62, Issue:10 Topics: Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Phlebotomy; Polycythemia Vera; Thrombosis	2021
Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19. British journal of haematology, 2021, Volume: 194, Issue:3 Topics: Adenosine Monophosphate; Adolescent; Alanine; Antimalarials; Antineoplastic Agents; Antiviral Agents	2021
Fanconi anemia proteins participate in a break-induced-replication-like pathway to counter replication stress. Nature structural & molecular biology, 2021, Volume: 28, Issue:6 Topics: Aneuploidy; Animals; Bone Marrow Failure Disorders; Cell Line, Transformed; Chickens; Chromosome Bre	2021
IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia. Frontiers of medicine, 2022, Volume: 16, Issue:3 Topics: Biomarkers; Humans; Hydroxyurea; Interferon Regulatory Factors; Janus Kinase 2; Leukemia, Myeloid, A	2022
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14 Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine;	2017
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia, 2018, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alleles; Disease Progression; Female; Gene Frequency; High-Throughpu	2018
Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:4 Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leuk	2019
JAK2 double minutes with resultant simultaneous amplification of JAK2 and CD274 in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukaemia. British journal of haematology, 2019, Volume: 185, Issue:3 Topics: Aged, 80 and over; B7-H1 Antigen; Gene Amplification; Humans; Hydroxyurea; Janus Kinase 2; Leukemia,	2019
Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm. Acta haematologica, 2018, Volume: 140, Issue:4 Topics: Aged; Decitabine; Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Acute; Male; Myelo	2018
Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis. Leukemia research, 2018, Volume: 75 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hemat	2018
Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine. Cell death & disease, 2019, 05-17, Volume: 10, Issue:6 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine Kinase; DNA D	2019
Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. British journal of haematology, 2014, Volume: 167, Issue:5 Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Databases, Factual;	2014
A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. British journal of haematology, 2015, Volume: 168, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Female	2015
Proteomic analysis of the response to cell cycle arrests in human myeloid leukemia cells. eLife, 2015, Jan-02, Volume: 4 Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Chromatin Assembly and Disassembly; Culture Media, Serum-F	2015
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:2 Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome	2015
Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget, 2016, Feb-16, Volume: 7, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anticonvulsants; Antineoplastic Agents; Apoptos	2016
Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Leukemia & lymphoma, 2016, Volume: 57, Issue:10 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Female; Ho	2016
The Use of Hydroxyurea and Leukapheresis in Childhood Acute Leukemia With Hyperleukocytosis. Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:5 Topics: Acute Disease; Child; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis	2016
Pleural effusion heralds acute leukemic transformation of chronic myelomonocytic leukemia. Southern medical journal, 2008, Volume: 101, Issue:12 Topics: Blast Crisis; Bone Marrow; Disease Progression; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia	2008
False positive Kleihauer results: an unusual cause in a postnatal patient in remission from acute myeloid leukaemia. International journal of laboratory hematology, 2009, Volume: 31, Issue:2 Topics: Adult; False Positive Reactions; Female; Fetal Hemoglobin; Hemoglobin A2; Humans; Hydroxyurea; Leuke	2009
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. Acta pharmacologica Sinica, 2009, Volume: 30, Issue:10 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine	2009
Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia. Journal of medical virology, 2010, Volume: 82, Issue:7 Topics: Adult; Antibiotics, Antineoplastic; Antibodies, Viral; Antigens, Viral; Antineoplastic Agents; Antiv	2010
Acute intraoperative tumour lysis syndrome. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2010, Volume: 57, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hydroxyurea; Leukemia, M	2010
Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia. Annals of internal medicine, 2011, Nov-15, Volume: 155, Issue:10 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male	2011
Are we underestimating the leukemogenic risk of hydroxyurea. Saudi medical journal, 2002, Volume: 23, Issue:11 Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia, Myeloid, Acute	2002
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. Annals of hematology, 2003, Volume: 82, Issue:8 Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cytogenetic Analysis; Dose-Response Relat	2003
GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:4 Suppl 2 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2005
When and how to treat essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia	2005
Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Female; Health Services for the Aged; Hu	2006
Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation. Leukemia, 2008, Volume: 22, Issue:7 Topics: Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Janus Kinase 2; Leukemi	2008
Megakaryoblastic transformation in myeloproliferative disorders. Cancer, 1984, Jul-15, Volume: 54, Issue:2 Topics: Blood Cell Count; Blood Platelets; Erythrocytes; Female; Hematopoietic Stem Cells; Histocytochemistr	1984
Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. The Journal of clinical investigation, 1984, Volume: 74, Issue:3 Topics: Cell Differentiation; Cell Division; Cell Line; Cell Survival; Clone Cells; Cytarabine; Heme; Hemogl	1984
High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study. Cancer, 1980, Apr-01, Volume: 45, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Child; Child, Pres	1980
[Results of complex treatment of adults with myeloblastic leukemia]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1980, Aug-04, Volume: 35, Issue:31 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Adm	1980
DNA-repair synthesis in blast cells from patients with acute myeloblastic leukaemia. Scandinavian journal of haematology, 1982, Volume: 28, Issue:5 Topics: Alkylating Agents; Autoradiography; Bone Marrow; Cell Transformation, Neoplastic; DNA; DNA Repair; H	1982
Terminal differentiation of the human promyelocytic leukemia cell line, HL-60, in the absence of cell proliferation. Cancer research, 1982, Volume: 42, Issue:11 Topics: Cell Cycle; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Cytarabine; Dimethyl Sulf	1982
Differential synchronization of leukemic cells in vivo by hydroxyurea. Leukemia research, 1982, Volume: 6, Issue:2 Topics: Cell Cycle; DNA Replication; Flow Cytometry; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukocyt	1982
Paroxysmal nocturnal hemoglobinuria with myelofibrosis: progression to acute myeloblastic leukemia. Leukemia & lymphoma, 1993, Volume: 12, Issue:1-2 Topics: Antigens, CD; Blood Proteins; CD55 Antigens; CD59 Antigens; Erythrocytes; Flow Cytometry; Granulocyt	1993
Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? European journal of haematology, 1995, Volume: 54, Issue:1 Topics: Administration, Oral; Aged; Busulfan; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukemi	1995
t(8;21) prior to acute leukemia. Cancer genetics and cytogenetics, 1993, Oct-15, Volume: 70, Issue:2 Topics: Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Female; Humans; Hydroxyurea; Leukemia, Myel	1993
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents. Haematologica, 1999, Volume: 84, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans;	1999
Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study. British journal of haematology, 2000, Volume: 108, Issue:1 Topics: Adult; Antineoplastic Agents; Biopsy; Cell Division; Cohort Studies; Female; Humans; Hydroxyurea; In	2000
[Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair	2000
Essential thrombocythemia transformed to acute myelogenous leukemia with t(3;17)(p24; q12), del(5)(q13q34) after treatment with carboquone and hydroxyurea. Japanese journal of clinical oncology, 2000, Volume: 30, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carbazilquinone; Chromosomes, Human, P	2000
[Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities]. Vnitrni lekarstvi, 1999, Volume: 45, Issue:8 Topics: Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Ac	1999
Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Annals of internal medicine, 2000, Dec-05, Volume: 133, Issue:11 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acu	2000
Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. Neoplasma, 2001, Volume: 48, Issue:5 Topics: Antineoplastic Agents; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 17; Disea	2001
DNA repair in human leukemic leucocytes treated with neocarzinostatin. Gan, 1978, Volume: 69, Issue:3 Topics: Adolescent; Adult; Antibiotics, Antineoplastic; DNA Repair; Dose-Response Relationship, Drug; Female	1978
Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Archives of internal medicine, 1977, Volume: 137, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Blood Cells; Female; Humans; Hydroxyurea; Leukemia, Lymphoid	1977
Extreme leucocytosis and prognosis of newly diagnosed patients with acute non-lymphocytic leukaemia. The Medical journal of Australia, 1979, Jun-02, Volume: 1, Issue:11 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hu	1979
The occurrence of antibodies against single-stranded DNA in the sera of patients with acute and chronic leukaemia. Clinical and experimental immunology, 1976, Volume: 24, Issue:3 Topics: Antibodies, Neoplasm; BCG Vaccine; DNA, Single-Stranded; Female; Follow-Up Studies; Humans; Hydroxyu	1976
Treatment of therapy-resistant acute myeloid leukaemia with 7 and 8 cytostatics. Scandinavian journal of haematology, 1975, Volume: 14, Issue:1 Topics: Adolescent; Adult; Aged; Candidiasis; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance; D	1975
Treatment of acute leukemia in adults. Cancer, 1975, Volume: 36, Issue:2 Topics: Adolescent; Adult; Aged; Asparaginase; Carmustine; Child; Cytarabine; Daunorubicin; Female; Humans;	1975
[Pharmakokinetics of hydroxy-urea. Therapy of acute myeoblastic leukemias using synchronization and recruitment effects (author' transl)]. Klinische Wochenschrift, 1976, Mar-01, Volume: 54, Issue:5 Topics: Administration, Oral; Adult; Cell Division; Cytarabine; DNA, Neoplasm; Half-Life; Humans; Hydroxyure	1976
Intensive therapy in elderly patients with acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leukemia, Mye	1990
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. Cancer chemotherapy and pharmacology, 1989, Volume: 25, Issue:3 Topics: Bone Marrow; Drug Evaluation; Drug Resistance; Drug Synergism; Humans; Hydroxyurea; Leukemia, Myeloi	1989
Induction of HL-60 monocytic cell differentiation promoted by a perturbation of DNA synthesis: hydroxyurea promotes action of TPA. Experimental cell research, 1988, Volume: 174, Issue:1 Topics: Cell Differentiation; Cell Division; Cell Line; Humans; Hydroxyurea; Kinetics; Leukemia, Myeloid, Ac	1988
High-voltage irradiation and hydroxyurea for pulmonary leukostasis in acute myelomonocytic leukemia. Acta haematologica, 1987, Volume: 77, Issue:3 Topics: Adult; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Lung Diseases; Male	1987
Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia, 1987, Volume: 1, Issue:5 Topics: Antigens, Surface; Benzamides; Cell Cycle; Cell Differentiation; Deferoxamine; DNA Repair; DNA, Neop	1987
Susceptibility of the human promyelocytic cell line HL-60 to an endogenous antileukaemic factor in suspension cultures. Cell biology international reports, 1986, Volume: 10, Issue:1 Topics: Cell Line; Cell Survival; Culture Media; DNA Replication; Flow Cytometry; Growth Inhibitors; Humans;	1986
Potentiation by 1-alpha,25-dihydroxyvitamin D3 of cytotoxicity to HL-60 cells produced by cytarabine and hydroxyurea. Journal of the National Cancer Institute, 1986, Volume: 76, Issue:4 Topics: Calcitriol; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Cytarabine; DNA, Neoplasm	1986
Hydroxyurea indices precommitment during retinoic induced HL-60 terminal myeloid differentiation: possible involvement of gene amplification. Leukemia research, 1987, Volume: 11, Issue:1 Topics: Cell Differentiation; Cell Division; Cell Line; DNA; DNA Replication; Humans; Hydroxyurea; Interphas	1987
Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia. Seminars in oncology, 1985, Volume: 12, Issue:2 Suppl 3 Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistan	1985
Effects of chemotherapy on bone marrow stroma in mice with acute myelogenous leukemia. Correlation with CFU-C and CFU-D. Leukemia research, 1985, Volume: 9, Issue:8 Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cytarabine; Diffusion; Doxorubicin;	1985
Effect of antimetabolites and thymidine blockage on the induction of differentiation of HL-60 cells by retinoic acid or 1 alpha,25-dihydroxyvitamin D3. Experimental hematology, 1985, Volume: 13, Issue:10 Topics: Antibiotics, Antineoplastic; Aphidicolin; Calcitriol; Cell Differentiation; Cell Division; Cell Line	1985
Philadelphia-chromosome-positive preleukaemic state. Lancet (London, England), 1972, Dec-09, Volume: 2, Issue:7789 Topics: Adult; Blood Cell Count; Bone Marrow Cells; Bone Marrow Examination; Chromosome Aberrations; Cytarab	1972
Combination chemotherapy of adult acute nonlymphoblastic leukemia. Annals of internal medicine, 1972, Volume: 76, Issue:3 Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Drug Synergism; Female; Humans; Hyd	1972
[Clinical trial of chemotherapeutic combinations based on the notion of attempted cellular synchronization. Preliminary administration of an antimitotic followed by the use of cycle-dependent or phase dependent product(s)]. La Nouvelle presse medicale, 1972, Jun-24, Volume: 1, Issue:26 Topics: Amino Sugars; Anthraquinones; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Daunorubicin; D	1972
The outlook for the adult with acute leukaemia, 1972. The Medical journal of Australia, 1972, Aug-19, Volume: 2, Issue:8 Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Cytarabine; Drug Combinations; Female;	1972
Daunorubicin-prednisone remission induction with hydroxyurea maintenance in acute non-lymphocytic leukemia. Cancer, 1973, Volume: 31, Issue:4 Topics: Adult; Age Factors; Daunorubicin; Female; Humans; Hydroxyurea; Leukemia, Erythroblastic, Acute; Leuk	1973
Optimism in leukemia treatment. Canadian Medical Association journal, 1973, Apr-07, Volume: 108, Issue:7 Topics: Acute Disease; Adult; Child; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia,	1973
[Therapy of acute leukemias]. Schweizerische medizinische Wochenschrift, 1973, Sep-22, Volume: 103, Issue:38 Topics: Adrenal Cortex Hormones; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug	1973
[Therapy of acute leukemia. Results of the Swiss study group for clinical cancer research (SAKK)]. Schweizerische medizinische Wochenschrift, 1974, Jan-26, Volume: 104, Issue:4 Topics: Age Factors; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; H	1974
Proliferative properties of malignant cell populations cultured in intraperitoneal diffusion chambers. European journal of cancer, 1973, Volume: 9, Issue:8 Topics: Animals; Cell Count; Cell Division; Cell Line; Cells, Cultured; Humans; Hydroxyurea; Leukemia, Myelo	1973
Comparative results obtained in the treatment of acute leukemia. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1973, Volume: 43 Topics: Antineoplastic Agents; Asparaginase; Carmustine; Cytarabine; Daunorubicin; Drug Therapy, Combination	1973
Drugs in the treatment of leukemia. British medical journal, 1968, Nov-02, Volume: 4, Issue:5626 Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L	1968
Studies on the effects of hydroxyurea and other anticancer drugs upon pyrimidine metabolism. Cancer research, 1969, Volume: 29, Issue:7 Topics: Amidohydrolases; Animals; Antineoplastic Agents; Ascites; Carbon Isotopes; Cyclophosphamide; Cytarab	1969
Studies on the absorption, distribution, and excretion of hydroxyurea (NSC-32065). Cancer chemotherapy reports, 1971, Volume: 55, Issue:2 Topics: Adult; Aged; Autopsy; Blood Cell Count; Erythrocytes; Female; Humans; Hydroxyurea; Leukemia, Myeloid	1971
Failure of hydroxyurea (NSC-32065) and prednisone (NSC-10023) in the treatment of acute myelocytic leukemia. Cancer chemotherapy reports, 1971, Volume: 55, Issue:2 Topics: Adult; Aged; Child; Female; Humans; Hydroxyurea; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged	1971

hydroxyurea and Leukemia, Myeloid, Acute